Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
| Revenue (TTM) | $17.35B |
| Gross Profit (TTM) | $9.03B |
| EBITDA | $5.00B |
| Operating Margin | 19.20% |
| Return on Equity | 21.60% |
| Return on Assets | 6.38% |
| Revenue/Share (TTM) | $15.09 |
| Book Value | $7.07 |
| Price-to-Book | 4.36 |
| Price-to-Sales (TTM) | 2.09 |
| EV/Revenue | 2.851 |
| EV/EBITDA | 15.13 |
| Quarterly Earnings Growth (YoY) | 72.20% |
| Quarterly Revenue Growth (YoY) | 2.30% |
| Shares Outstanding | $1.16B |
| Float | $1.08B |
| % Insiders | 0.00% |
| % Institutions | 63.33% |
Volatility is currently expanding
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Besides Wall Street's top-and-bottom-line estimates for Teva Pharmaceutical Industries (TEVA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Teva's pivot toward branded drugs is benefiting the company's underlying performance and its stock price. While shares have pulled back recently, another big catalyst could play out in the years ahead.
Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for branded medicines and and key policy details remain unclear.
Teva Pharmaceutical Industries NYSE: TEVA said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the company highlighted the program as part of its broader shift toward a biopharma-focused growth strategy.
Teva secures exclusive global rights to commercialize Polpharma Biologics' biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva's Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.
Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b Transcript
TEVA is expanding its branded drugs portfolio as Austedo, Ajovy and Uzedy drive higher-margin growth and reshape its business mix.
TEVA files an NDA with the FDA seeking approval of ecopipam for the treatment of pediatric Tourette syndrome.
TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a first-in-class investigational therapy for the treatment of pediatric Tourette syndrome.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TEVA and any ticker you trade — then tracks every position and per-strategy win rate.
